Neoadjuvant TAR-200/Cetrelimab Combo Generates Responses in Muscle-Invasive Bladder Cancer
Adding Relatlimab to Nivolumab/Chemo Did Not Increase Toxicity
Hypofractionated Radiation Noninferior for Lymphedema Prevention in Early Breast Cancer
Perioperative Durvalumab With Neoadjuvant Chemo Boosts Survival in Cisplatin-Eligible MIBC